Overview
- Unloxcyt (cosibelimab-ipdl) is now available in the U.S. for adults with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or radiation.
- Prescribing access runs through a limited network of authorized specialty distributors plus one contracted specialty pharmacy.
- Sun Pharma describes the therapy as an evolution in checkpoint inhibition with durable efficacy and a proven tolerability profile, according to North America CEO Richard Ascroft.
- The company estimates about 40,000 U.S. patients progress to advanced disease each year, leading to nearly 15,000 deaths.
- Following the announcement, Sun Pharma shares were reported down 2.2% at Rs 1,663.20 on the BSE at the time of publication.